title: Serum prohepcidin and hepcidin in hemodialyzed patients undergoing iron therapy.
abstract: Hepcidin is the predominant negative regulator of iron absorption in the small intestine, iron transport across the placenta, and iron release from the macrophages. Iron supplementation is often introduced in dialyzed patients to replete or to maintain iron stores, particularly in patients treated with erythropoietin-stimulating agents. The aim of this study was to assess hepcidin levels in 12 hemodialyzed (HD) patients (6 females, 6 males, mean age 64 years, mean time on HD 36 months) before and after intravenous iron therapy. Prohepcidin and hepcidin were studied using commercially available kits from DRG Instruments GmbH, Marburg, Germany (ELISA method), and Bachem, St. Helens, UK (RIA method). Soluble receptor of transferrin was studied using a kit from R&D, Abington, UK. We found a significant rise in hemoglobin concentration, hematocrit, ferritin, serum iron, transferrin saturation and a fall in soluble receptor of transferrin. Serum hepcidin and prohepcidin as well as urinary prohepcidin increased significantly after the therapy. In conclusion, hepcidin levels are influenced by iron supplementation in HD patients. Further examinations of hepcidin as a marker of iron deficiency using new validated measurement techniques are required. It remains to be seen if assay of hepcidin will be of help in identifying patients unresponsive to oral iron or requiring intravenous iron supplementation.
authors.affiliation: Department of Nephrology and Transplantology, Medical University, Bialystok, Poland. jolmal@poczta.onet.pl
authors.forename: Jolanta
authors.initials: J
authors.lastname: Malyszko
authors.forename: Jacek S
authors.initials: JS
authors.lastname: Malyszko
authors.forename: Michal
authors.initials: M
authors.lastname: Mysliwiec
mesh_terms: D000368:Aged; D023181:Antimicrobial Cationic Peptides / Q000097:blood*; D005260:Female; D005293:Ferritins / Q000097:blood; D006400:Hematocrit; D064451:Hepcidins; D006801:Humans; D007275:Injections, Intravenous; D007501:Iron / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011498:Protein Precursors / Q000097:blood*; D006435:Renal Dialysis; D014168:Transferrin / Q000378:metabolism
chemical_list: D023181:Antimicrobial Cationic Peptides; C578702:HAMP protein, human; D064451:Hepcidins; D011498:Protein Precursors; D014168:Transferrin; D005293:Ferritins; D007501:Iron